Early stage compounds and new filings targeted in five therapeutic areas
Expanding indications for strong core products builds "pipeline in a product"
Leveraging global capabilities and reach drives growth efforts in emerging markets
Biomarkers and diagnostics combine with therapies to advance personalized medicine
Company's vision focuses on improving human health and reducing global burden of disease
NEW BRUNSWICK, N.J., June 4 /PRNewswire-FirstCall/ -- Johnson & Johnson will be reviewing the growth strategies and pipeline for its Pharmaceutical business at a meeting with the investment community today. Senior leaders from the company's pharmaceutical segment will outline how continued expansion of its core products, progress in its pipeline, and an end-to-end approach to its research and development (R&D) will fuel its long-term growth and address unmet medical needs.
The company will highlight its plans for addressing these needs in five therapeutic areas:
Brief summaries of the therapeutic areas, products and compounds being discussed in today's presentations are available in this backgrounder: Pharmaceutical Segment Review Highlights.
Pharmaceutical Growth Strategies
Johnson & Johnson's pharmaceutical businesses generated $24.6 billion in sales last year, 39 percent of the company's total revenue, and ranks as the world's seventh largest pharmaceutical company and fourth largest biotech company. Its portfolio includes nine products that delivered more than $1 billion in sales in 2008. Its recent pace of regulatory filings, approvals and line extensions place it among the industry leaders and its robust pipeline positions it well for continued success.
"We are very optimistic about our future in pharmaceuticals," says Worldwide Chairman of Pharmaceuticals Sheri McCoy. "We are well-positioned with an industry-leading pipeline, the global reach and financial resources of Johnson & Johnson, a long, rich history in pharmaceuticals, and a broad portfolio that is grounded in science and addresses serious unmet needs."
With the pharmaceutical market at an estimated $750 billion globally, McCoy will outline five strategies for growth for the company's pharmaceutical businesses:
Fueling Growth Through Innovation
Paul Stoffels, M.D., global head of Research and Development for Pharmaceuticals, will report today on the business' recent track record of pipeline productivity and its long-term strategy for addressing some of the most important unmet medical needs in the world today.
"Our pipeline productivity is on track. In fact, 2008 was a year of significant submissions and approvals for us," says Stoffels. "We had six new compounds approved in major markets, and we have seven compounds with filings pending in the U.S. and Europe. We also had outstanding late-stage development progress, with five compounds advancing to late development. And, finally, we expanded our portfolio through licensing, collaborations, and creating new partnerships in emerging regions such as India and China."
Johnson & Johnson invested just over $5 billion in pharmaceutical R&D programs last year. "Innovation and sustained R&D productivity are key to our long-term future," says Stoffels. "The future drivers for success in pharmaceuticals will depend on matching the medical need with the best science and operational excellence. It will require that we have a therapeutic area focus, an open innovation approach, an outcomes-based drug development strategy, broad-based expertise and global reach, and truly outstanding people."
The company is continuing to advance its pipeline of new compounds, while also exploring line extensions for existing drugs, which have the potential to become what the company calls a "pipeline in a product." Among some of the early stage compounds being discussed today are the company's first compound for treating type 2 diabetes, the SGLT2 inhibitor, and CNTO-888, which has the potential for indications in both immunology and oncology. Stoffels and other executives will discuss the company's expectations for new filings and early-stage compounds across each of the five therapeutic areas throughout the day.
"Our pipeline is robust and consists of compounds that are differentiated and meet unmet needs in global and large regional markets. And our commercial teams around the world are working to deliver enhanced clinical and economic value," says McCoy. "All of this together gives me great confidence in our ability to make a real difference in patients' lives."
Full copies of the presentations as well as a replay and podcast will be available approximately two hours after the live webcast concludes at www.investor.jnj.com.
About Johnson & Johnson
Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents obtained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.
This press release contains statements about new molecular entities ("NMEs") and other medicines or line extensions in various stages of development. These statements are based on the Company's current knowledge of the status of development of these NMEs, medicines and line extensions and are subject to the challenges and difficulties inherent in product development. The Company assumes no obligation to update any statements regarding these NME, medicines or line extensions as a result of new information or future events or developments. In biopharmaceuticals, there are higher possibilities of encountering infringement claims by competitors with respect to patents or other intellectual property rights. The Company assumes no obligation to update any statements as a result of new information or future events or developments.)
CONTACT: Press, Jeffrey J. Leebaw, +1-732-524-3350, +1-732-642-6608 (M),
or Bill Price, +1-732-524-6623, +1-732-668-3735 (M), or Investors, Louise
Mehrotra, +1-732-524-6491, or Lesley Fishman, +1-732-524-3922, or Tina
Pinto, +1-732-524-2034, all of Johnson & Johnson
Web site: http://www.jnj.com/
